Indivior Q2 2026: Record Revenue, Raised Guidance, and a $1B Special Dividend Ahead of the Supernus Merger
INDV sits 88% above its 52-week low of $19.75 on elevated volume (3.4× avg).
Summary
Indivior posted record Q2 2026 results with 21% SUBLOCADE growth, raised full-year guidance, and announced a merger with Supernus that includes a $1 billion special dividend for Indivior shareholders.
Key Events · Earnings and Guidance · INDV
-
Record Q2 Revenue and Profit
Net revenue rose 14% to $343M, driven by SUBLOCADE U.S. sales of $238M (up 22%). Net income was $122M, or $0.98 diluted EPS, compared to $18M a year ago.
-
Full-Year Guidance Raised
Management increased 2026 revenue guidance to $1.295B–$1.365B, up from a prior midpoint of roughly $1.25B, reflecting strong SUBLOCADE momentum.
-
Merger with Supernus Announced
On August 1, 2026, Indivior agreed to an all-stock merger of equals with Supernus Pharmaceuticals. Indivior shareholders will own ~56.5% of the combined company, which will retain the Supernus name.
-
$1B Special Dividend Pre-Merger
Indivior will pay a $1 billion special cash dividend to its stockholders immediately before the merger closes, funded by $650M in new term loan commitments and cash on hand.
Analysis · INDV · Life Sciences
A standout quarter saw SUBLOCADE fuel 22% U.S. revenue growth and operating income more than double. Full-year guidance was raised, and an all-stock merger with Supernus was announced—reshaping the combined CNS-focused entity. Just before closing, a $1 billion special dividend, funded partly by new debt, will be paid to Indivior stockholders. The period also featured aggressive share buybacks and a restructuring that halted two pipeline programs, refocusing the business entirely on its commercial OUD franchise. While the merger and special dividend dominate the narrative, the underlying operational strength provides a solid foundation for the deal.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 40.6% of the 409 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INDV was trading at $37.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.6B. The 52-week trading range was $19.75 to $42.81. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.